Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Obesity, Overweight
In brief
The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participant will get is decided by chance. The study will last for about 8 months.
Key facts
- Study ID
- NCT07607587
- Run by
- Novo Nordisk A/S
- People needed
- 114
- Starts
- 2026-05-29
- Expected to finish
- 2027-11-19
- Last updated by the study team
- 2026-06-25
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Elligo Clin Res Centre — Austin, Texas, United States (enrolling)
- Northeast Research Institute — Fleming Island, Florida, United States (enrolling)
- Jacksonville Ctr For Clin Res — Jacksonville, Florida, United States (enrolling)
- Center for Diab,Obes & Metab — Pembroke Pines, Florida, United States (enrolling)
- Encore Medical Research of Weston — Weston, Florida, United States (enrolling)
- Monroe Biomedical Research, LLC — Monroe, North Carolina, United States (enrolling)
- Accellacare — Wilmington, North Carolina, United States (enrolling)
- Diablo Clinical Research, Inc. — Walnut Creek, California, United States (enrolling)
- Holston Medical Group_Bristol — Bristol, Tennessee, United States (enrolling)
- Amarillo Medical Specialists — Amarillo, Texas, United States (enrolling)
- Coastal Carolina Research Ctr — North Charleston, South Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.